MSM is desperate to come up with anything to demonize Chinese vaccines. They use a study from bias researchers with unknown test kit to discredit Sinopharm vaccine effectiveness against elderly by saying not enough antibodies are detected among elderly.
China’s National Health Commission declined to comment on the study, saying it would only respond to studies by governments or major research institutions.
On the other hand, Peru government study of Sinopharm effectiveness is rarely reported in the West. Peru study is important as it has multiple new variants such as Gamma and Lambda.
INS: Sinopharm vaccine is up to 94% effective in reducing death from COVID-19
The director of the INS, Víctor Suárez, said that the studies carried out on the Sinopharm vaccine show that this dose prevents death and is in line with the doses from other laboratories. Along these lines, he urged citizens to stop fear and get vaccinated.
Víctor Suárez Moreno, director of the National Institute of Health (INS), pointed out this Thursday that a recent study shows that the Sinopharm vaccine has an effectiveness of up to 94%, to reduce the risk of death in those who received the doses from said laboratory.
As he explained to Espacio Vital of RPP Noticias, the study carried out collaboratively between INS, the Southern Scientific University and the Institute for the Evaluation of Health Technologies crossed information from health workers in various databases, to determine what was the effectiveness of the Sinopharm vaccine they received.
He specified that they analyzed a significant number of data with 61,000 unvaccinated people and 300,000 people who received the inoculation. Thus, the results indicate that the effectiveness of the Sinopharm vaccine in reducing the risk of death reaches 94%.
"We have taken the Inforhus databases where the health workers and the vaccines they have received are, we have used the Medlab and Ciscovid databases, where the results of the molecular and antigenic tests are, and we have used the database of data from Sinadef, where the deaths are, ”he said.
"The most relevant data is in relation to mortality. What we found is that the Sinopharm vaccine is 94% effective for mortality, it has a strong impact (...) Death from COVID-19 specifically, because there is also general death, 90% effective, but death from COVID-19 it is 94% ”, he indicated.
The specialist also mentioned that they have been able to show that the immune response of the Sinopharm vaccine is very high and that at least 99% of those vaccinated have antibodies against COVID-19.
However, he stressed that the response of the first dose from the Chinese laboratory is different, when the person already had a history or not of the infection. Along these lines, he explained that a person who has a history of COVID-19 develops more antibodies than someone who did not have the infection.
“What has caught our attention is that the response to the first dose is different when it is a person with or without a history of infection. For example, those who do not have a history of infection, 15 to 30% develop antibodies with one dose, while if they have a history of infection, they have had disease before, this rises to 82% or 77% with just one dose " , he indicated.
Suárez assured that from the INS they are working to promote the vaccination process against COVID-19 at the national level and to remove the fear of people so that the inoculations are applied. In this regard, he reiterated that the Sinopharm vaccine "prevents death and is in line with what happens with other vaccines as well."